v3.24.1.1.u2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues    
Service $ 39,776 $ 5,356
Product 131,759 144,452
Total Revenues 171,535 149,808
Operating Expenses    
Research and development 4,629,527 4,905,678
General and administrative 2,253,743 2,581,703
Sales and marketing 1,672,769 1,707,457
Total Operating Expenses 8,556,039 9,194,838
Operating Loss (8,384,504) (9,045,030)
Other Income (Expenses)    
Grant income 0 165,795
Interest income 8,654 57,648
Interest expense (77,233) (51,322)
Loss on change in fair value of warrant liability (18,922) 0
Total Other Income (Expenses) (87,501) 172,121
Net Loss (8,472,005) (8,872,909)
Net Loss attributable to Non-Controlling Interest 104,617 93,361
Net Loss attributable to VolitionRx Stockholders (8,367,388) (8,779,548)
Other Comprehensive Income (Loss)    
Foreign currency translation adjustments 15,026 (56,478)
Net Comprehensive Loss $ (8,456,979) $ (8,929,387)
Net Loss Per Share - Basic and Diluted attributable to VolitionRx Stockholders $ (0.10) $ (0.15)
Weighted Average Shares Outstanding - Basic and Diluted 81,956,660 60,176,975

Source

10-Q PDF
XBRL